ArticleEJNMMI physics2020
Kidney dosimetry in 777 patients during
Article in EJNMMI physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dosimetry of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Pooled it
- Beyond the Fixed Dose in Theranostics: Pragmatic Dosimetry as the Missing Link in Optimizing Precision Nuclear Oncology.World journal of nuclear medicine · 2026Article
- Outcome-driven dosimetry optimization for [European journal of nuclear medicine and molecular imaging · 2026Article
- Pulling Together: A 5-Year Plan to Improve Theranostic Outcomes by Improving the Accuracy of Dosimetry-An FNIH Joint Academic, Clinical, and Industrial Collaboration.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- FAP-Targeted Radionuclide Therapy: Mechanisms, Clinical Applications, and Combination Strategies.Biomedicines · 2026Review
- Validation of Simplified Renal Dosimetry Protocols forMolecular imaging and radionuclide therapy · 2026Article
- Continuous βClinical and translational radiation oncology · 2025Article
- Feasibility of individual dosimetry using RT-PHITS for patients with SPECT/CT imaging afterPhysical and engineering sciences in medicine · 2025Article
- On the reduction of imaging time-points for dosimetry in radionuclide therapy.EJNMMI physics · 2025Article
- Dosimetry Software for Theranostic Applications: Current Capabilities and Future Prospects.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.EJNMMI research · 2024Article
- The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience.Current oncology (Toronto, Ont.) · 2024Article
- Estimation of kidney doses from [EJNMMI physics · 2024Article
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- Prediction of [EJNMMI physics · 2024Article
- Activity quantification and dosimetry in radiopharmaceutical therapy with reference toFrontiers in nuclear medicine · 2024Review
- Single-Time-Point Imaging for Dosimetry After [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.European journal of nuclear medicine and molecular imaging · 2023Article
- Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms.Cancers · 2023Review
- Theranostics and Patient-Specific Dosimetry.Seminars in radiation oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFractionated peptide receptor radionuclide therapy (PRRT) with
methodsIn 777 patients with disseminated neuroendocrine tumors undergoing PRRT, SPECT/CT over the abdomen was acquired at 1, 4, and 7 days after
resultsThe fractional contributions from extrapolations before day 1 measurement and after day 7 measurement were approximately 26% and 11%, respectively. The mean differences in absorbed dose, based on one, two, and three time points were small, but with high method dependence for individual patients. The differences in estimated t
conclusionWhen assessing simplifications of methods for calculation of the absorbed dose to the kidneys, it was of the uttermost importance to incorporate the fractional contribution for the extrapolations included in the reference method. Measurements at an early and a late time point were found most important. An intermediate measurement contributes with an idea of the goodness of the fit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.